Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C14H12ClN3O2.ClH |
Molecular Weight | 326.178 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.[H][C@]1(CCCN1)C2=NC3=C(OC4=C3C=C(Cl)C=C4)C(=O)N2
InChI
InChIKey=UNDKJUKLBNARIZ-FVGYRXGTSA-N
InChI=1S/C14H12ClN3O2.ClH/c15-7-3-4-10-8(6-7)11-12(20-10)14(19)18-13(17-11)9-2-1-5-16-9;/h3-4,6,9,16H,1-2,5H2,(H,17,18,19);1H/t9-;/m0./s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/22560567Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/20647475
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22560567
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/20647475
BMS-863233, also known as XL413, is a potent and selective cell division cycle 7 (CDC7) kinase inhibitor with potential antineoplastic activity. BMS-863233 binds to and inhibits the activity of CDC7, which may result in the inhibition of DNA replication and mitosis, the induction of tumor cell apoptosis, and the inhibition of tumor cell proliferation in CDC7-overexpressing tumor cells. CDC7, a serine-threonine kinase overexpressed in a variety of tumor cell types, plays an essential role in the initiation of DNA replication by activating origins of replication.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22560567
Curator's Comment: # Exelixis
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL5443 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22560567 |
3.4 nM [IC50] | ||
Target ID: CHEMBL3038477 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22560567 |
215.0 nM [IC50] | ||
Target ID: CHEMBL2147 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22560567 |
42.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | BMS-63233 Approved UseUnknown |
|||
Primary | BMS-63233 Approved UseUnknown |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22560567
Prolonged treatment with BMS-863233 (XL413) during 3 days inhibited the cell proliferation (IC50 = 2685 nM), decreased cell viability (IC50 = 2142 nM) and elicited the caspase 3/7 activity (EC50 = 2288 nM) in human colorectal adenocarcinoma Colo-205 cells.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
135564631
Created by
admin on Fri Dec 15 17:42:11 GMT 2023 , Edited by admin on Fri Dec 15 17:42:11 GMT 2023
|
PRIMARY | |||
|
DBSALT002181
Created by
admin on Fri Dec 15 17:42:11 GMT 2023 , Edited by admin on Fri Dec 15 17:42:11 GMT 2023
|
PRIMARY | |||
|
1169562-71-3
Created by
admin on Fri Dec 15 17:42:11 GMT 2023 , Edited by admin on Fri Dec 15 17:42:11 GMT 2023
|
PRIMARY | |||
|
JG305JRH1Z
Created by
admin on Fri Dec 15 17:42:11 GMT 2023 , Edited by admin on Fri Dec 15 17:42:11 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD